A Phase Ia clinical trial to assess the safety and immunogenicity of the blood-stage malaria candidate vaccines RH5.1 in Matrix-MTM and R78C in Matrix-MTM, both alone and in combination, in healthy UK adults (VAC089)

Research summary

Malaria is an infectious disease caused by a parasite which is spread by the bite of aninfected mosquito. There were around 240 million cases of malaria and 627,000 deathsworldwide in 2020. There is a great need for a safe,eff ective malaria vaccine and the team atUniversity of Oxford is trying to make vaccine(s) which can prevent serious illness and death. This study is being done to evaluate two experimental malaria vaccines for their safety. Wewill also look at the body’s immune response to the vaccines. The vaccines we are testing inthis study are called “R78C” and “RH5.1”. They are given with an adjuvant called “Matrix-M”.An adjuvant is a substance to improve the body’s response to a vaccination. The aim is to use the vaccines and adjuvant to help the body make an immune responseagainst parts of the malaria parasite. This study will assess: 1. The safety of the vaccines in healthy participants. 2. The response of the human immune system to the vaccines. We will do this by giving healthy adult participants (aged 18-45) three or four doses of thevaccines at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM),ChurchillHospital in Oxford. We will then do blood tests and collect information about any symptomsthat occur after vaccination. There will be 19 to 23 visits,lasting between 12 to 20 months.

Principal Investigator

Dr Angela Minassian

Contact us

Email: vaccinetrials@ndm.ox.ac.uk

IRAS number

1005709